1
|
Zaidan S, Abdillah S, Arfian N, Arozal W. Hypolipidemic effect of brown seaweed ( Sargassum crassifolium) extract in vivo (Study of histopathology, mRNA expression, and immunohistochemistry (IHC) with VCAM-1, ICAM-1, and MCP-1 parameters). ArXiv 2024:arXiv:2402.07497v1. [PMID: 38410655 PMCID: PMC10896358] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 02/28/2024]
Abstract
The purpose of this study was to obtain natural drugs from brown seaweed (Sargassum crassifolium) as antiatherosclerosis candidates through the study of hypolipidemic mechanisms of action. Modeling of dyslipidemia rats was carried out by feeding high-fat (HFF) and doses of crude fucoidan 100. 200. 400mg / KgBB. in both treatments measured blood lipid profile levels taken from the orbital sinuses. HE's histopathology. mRNA expression. immunohistochemistry (IHC) with parameters VCAM-1. ICAM-1. and MCP-1 were performed on adipose tissue. as well as liver. Total cholesterol values 51.07-225.2. triglycerides 30.43-115.73. HDL 13.1-24.86 mg/dl and LDL 20.22-189.68 mg/dl. In the treatment of crude fucoidan obtained the result of p value < α (0.05. Histopathological features of adipose tissue after administration of HFF for 60 days resulted in an increase in adipose cell size. and the liver experienced structural damage and inflammation. but after 21 days of treatment the morphological picture of adipose tissue was similar to normal morphology and the liver also decreased in severity and inflammation. The results of histochemical staining after treatment showed a positive staining part on MCP-1. The result of p value < α (0.05) of mRNA expression for administration of 3 treatment doses. A dyslipidemic mouse model with HFF administration for 60 days succeeded in becoming a dyslipidemic rat. and crude fucoidan had hypolipidemic activity. Doses of 100. 200. and 400 mg/KgBB crude fucoidan showed improvement in adipose and liver morphological features of severity and inflammation of dyslipidemic rats and decreased mRNA expression.
Collapse
Affiliation(s)
- Sarah Zaidan
- Faculty of Pharmacy, Universitas Pancasila, Srengseng Sawah, Jagakarsa, South Jakarta, Indonesia 12640
| | - Syamsudin Abdillah
- Faculty of Pharmacy, Universitas Pancasila, Srengseng Sawah, Jagakarsa, South Jakarta, Indonesia 12640
| | - Nur Arfian
- Department of Anatomy, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Farmako St., Sekip Utara, Senolowo, Sinduadi, Mlati, Sleman regency, Yogyakarta 55281
| | - Wawaimuli Arozal
- Department of Pharmacology and Therapeutics, Faculty of Medicine, University of Indonesia Salemba Raya St. No. 6, Jakarta 10430
| |
Collapse
|
2
|
El-Far M, Durand M, Turcotte I, Larouche-Anctil E, Sylla M, Zaidan S, Chartrand-Lefebvre C, Bunet R, Ramani H, Sadouni M, Boldeanu I, Chamberland A, Lesage S, Baril JG, Trottier B, Thomas R, Gonzalez E, Filali-Mouhim A, Goulet JP, Martinson JA, Kassaye S, Karim R, Kizer JR, French AL, Gange SJ, Ancuta P, Routy JP, Hanna DB, Kaplan RC, Chomont N, Landay AL, Tremblay CL. Upregulated IL-32 Expression And Reduced Gut Short Chain Fatty Acid Caproic Acid in People Living With HIV With Subclinical Atherosclerosis. Front Immunol 2021; 12:664371. [PMID: 33936102 PMCID: PMC8083984 DOI: 10.3389/fimmu.2021.664371] [Citation(s) in RCA: 21] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2021] [Accepted: 03/26/2021] [Indexed: 12/22/2022] Open
Abstract
Despite the success of antiretroviral therapy (ART), people living with HIV (PLWH) are still at higher risk for cardiovascular diseases (CVDs) that are mediated by chronic inflammation. Identification of novel inflammatory mediators with the inherent potential to be used as CVD biomarkers and also as therapeutic targets is critically needed for better risk stratification and disease management in PLWH. Here, we investigated the expression and potential role of the multi-isoform proinflammatory cytokine IL-32 in subclinical atherosclerosis in PLWH (n=49 with subclinical atherosclerosis and n=30 without) and HIV- controls (n=25 with subclinical atherosclerosis and n=24 without). While expression of all tested IL-32 isoforms (α, β, γ, D, ϵ, and θ) was significantly higher in peripheral blood from PLWH compared to HIV- controls, IL-32D and IL-32θ isoforms were further upregulated in HIV+ individuals with coronary artery atherosclerosis compared to their counterparts without. Upregulation of these two isoforms was associated with increased plasma levels of IL-18 and IL-1β and downregulation of the atheroprotective protein TRAIL, which together composed a unique atherosclerotic inflammatory signature specific for PLWH compared to HIV- controls. Logistic regression analysis demonstrated that modulation of these inflammatory variables was independent of age, smoking, and statin treatment. Furthermore, our in vitro functional data linked IL-32 to macrophage activation and production of IL-18 and downregulation of TRAIL, a mechanism previously shown to be associated with impaired cholesterol metabolism and atherosclerosis. Finally, increased expression of IL-32 isoforms in PLWH with subclinical atherosclerosis was associated with altered gut microbiome (increased pathogenic bacteria; Rothia and Eggerthella species) and lower abundance of the gut metabolite short-chain fatty acid (SCFA) caproic acid, measured in fecal samples from the study participants. Importantly, caproic acid diminished the production of IL-32, IL-18, and IL-1β in human PBMCs in response to bacterial LPS stimulation. In conclusion, our studies identified an HIV-specific atherosclerotic inflammatory signature including specific IL-32 isoforms, which is regulated by the SCFA caproic acid and that may lead to new potential therapies to prevent CVD in ART-treated PLWH.
Collapse
Affiliation(s)
- Mohamed El-Far
- University of Montreal Hospital Centre (CRCHUM)-Research Centre, Montréal, QC, Canada
| | - Madeleine Durand
- University of Montreal Hospital Centre (CRCHUM)-Research Centre, Montréal, QC, Canada.,Département de Microbiologie, Infectiologie et Immunologie, Faculté de Médecine, Université de Montréal, Montréal, QC, Canada
| | - Isabelle Turcotte
- University of Montreal Hospital Centre (CRCHUM)-Research Centre, Montréal, QC, Canada.,Département de Microbiologie, Infectiologie et Immunologie, Faculté de Médecine, Université de Montréal, Montréal, QC, Canada
| | | | - Mohamed Sylla
- University of Montreal Hospital Centre (CRCHUM)-Research Centre, Montréal, QC, Canada
| | - Sarah Zaidan
- University of Montreal Hospital Centre (CRCHUM)-Research Centre, Montréal, QC, Canada.,Département de Microbiologie, Infectiologie et Immunologie, Faculté de Médecine, Université de Montréal, Montréal, QC, Canada
| | - Carl Chartrand-Lefebvre
- University of Montreal Hospital Centre (CRCHUM)-Research Centre, Montréal, QC, Canada.,Département de Radiologie, Radio-oncologie et Médecine Nucléaire, Faculté de Médecine, Université de Montréal, Montréal, QC, Canada
| | - Rémi Bunet
- University of Montreal Hospital Centre (CRCHUM)-Research Centre, Montréal, QC, Canada.,Département de Microbiologie, Infectiologie et Immunologie, Faculté de Médecine, Université de Montréal, Montréal, QC, Canada
| | - Hardik Ramani
- University of Montreal Hospital Centre (CRCHUM)-Research Centre, Montréal, QC, Canada.,Département de Microbiologie, Infectiologie et Immunologie, Faculté de Médecine, Université de Montréal, Montréal, QC, Canada
| | - Manel Sadouni
- University of Montreal Hospital Centre (CRCHUM)-Research Centre, Montréal, QC, Canada
| | - Irina Boldeanu
- University of Montreal Hospital Centre (CRCHUM)-Research Centre, Montréal, QC, Canada
| | - Annie Chamberland
- University of Montreal Hospital Centre (CRCHUM)-Research Centre, Montréal, QC, Canada
| | - Sylvie Lesage
- Département de Microbiologie, Infectiologie et Immunologie, Faculté de Médecine, Université de Montréal, Montréal, QC, Canada.,Hôpital Maisonneuve-Rosemont, Montréal, QC, Canada
| | - Jean-Guy Baril
- Centre de médecine urbaine du Quartier latin, Montréal, QC, Canada
| | - Benoit Trottier
- Centre de médecine urbaine du Quartier latin, Montréal, QC, Canada
| | | | - Emmanuel Gonzalez
- Department of Human Genetics, Canadian Centre for Computational Genomics, McGill University, Montreal, QC, Canada.,Microbiome Platform Research, McGill Interdisciplinary Initiative in Infection and Immunity, McGill University, Montreal, QC, Canada
| | - Ali Filali-Mouhim
- University of Montreal Hospital Centre (CRCHUM)-Research Centre, Montréal, QC, Canada
| | | | - Jeffrey A Martinson
- Department of Internal Medicine, Rush University Medical Center, Chicago, IL, United States
| | - Seble Kassaye
- Department of Medicine, Georgetown University, Washington, DC, United States
| | - Roksana Karim
- Department of Preventive Medicine, University of Southern California, Los Angeles, CA, United States
| | - Jorge R Kizer
- Cardiology Section, San Francisco Veterans Affairs Health Care System, San Francisco, CA, United States.,Departments of Medicine, Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA, United States
| | - Audrey L French
- Division of Infectious Diseases, Stroger Hospital of Cook County, Chicago IL, United States
| | - Stephen J Gange
- Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, United States
| | - Petronela Ancuta
- University of Montreal Hospital Centre (CRCHUM)-Research Centre, Montréal, QC, Canada.,Département de Microbiologie, Infectiologie et Immunologie, Faculté de Médecine, Université de Montréal, Montréal, QC, Canada
| | - Jean-Pierre Routy
- Research Institute of McGill University Health Centre, Montréal, QC, Canada
| | - David B Hanna
- Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY, United States
| | - Robert C Kaplan
- Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY, United States.,Divsion of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, United States
| | - Nicolas Chomont
- University of Montreal Hospital Centre (CRCHUM)-Research Centre, Montréal, QC, Canada.,Département de Microbiologie, Infectiologie et Immunologie, Faculté de Médecine, Université de Montréal, Montréal, QC, Canada
| | - Alan L Landay
- Department of Internal Medicine, Rush University Medical Center, Chicago, IL, United States
| | - Cécile L Tremblay
- University of Montreal Hospital Centre (CRCHUM)-Research Centre, Montréal, QC, Canada.,Département de Microbiologie, Infectiologie et Immunologie, Faculté de Médecine, Université de Montréal, Montréal, QC, Canada
| |
Collapse
|